Neuroendocrine Tumors (NETs & PNETs)

Classification, grading, and treatment of gastroenteropancreatic and other neuroendocrine neoplasms — from well-differentiated carcinoids to poorly differentiated high-grade NEC

Key Points

• NETs are classified by site of origin and grade (G1–G3 by Ki-67/mitotic rate); well-differentiated NETs and poorly differentiated neuroendocrine carcinomas (NECs) have distinct biology and treatment.
• GEP-NETs (gastroenteropancreatic) are the most common NETs; small intestinal NETs are the most frequent GEP subtype; pancreatic NETs (PNETs) are a distinct subset with unique therapeutic options.
• Gallium-68 DOTATATE PET/CT is the preferred functional imaging modality for somatostatin receptor (SSTR)-positive NETs and has largely replaced Octreoscan.
• Somatostatin analogs (octreotide LAR, lanreotide) control hormonal symptoms and have antiproliferative activity in well-differentiated NETs (PROMID, CLARINET trials).
• Lu-177 dotatate (PRRT — peptide receptor radionuclide therapy) is a potent option for SSTR-positive, well-differentiated, progressive midgut NETs (NETTER-1 trial).
• PNETs have additional targeted options: everolimus (RADIANT-3) and sunitinib (SUN1111), both FDA-approved for progressive well-differentiated PNETs.
• High-grade poorly differentiated NEC is treated with platinum-etoposide chemotherapy (analogous to SCLC), distinct from the management of well-differentiated G3 NETs.
• Cytotoxic sequencing is subtype-specific: midgut carcinoids progress SSA → PRRT → FOLFOX; pNETs progress SSA → PRRT/targeted → CAPTEM (MGMT-methylated) or streptozocin-based regimens (MGMT-unmethylated or refractory).

Classification & Grading

Neuroendocrine neoplasms (NENs) arise from cells of the diffuse neuroendocrine system and are remarkably heterogeneous. The 2022 WHO classification framework applies across all sites and distinguishes two fundamental categories: Well-differentiated neuroendocrine tumors (NETs): These tumors retain organoid architecture and neuroendocrine morphology and are graded by proliferative activity: • G1 NET: Ki-67 index 20%; biologically distinct from poorly differentiated NEC — better prognosis and different treatment approach Poorly differentiated neuroendocrine carcinoma (NEC): High-grade neoplasm…

Epidemiology & Incidence

The incidence of NETs has increased ~6-fold over the past four decades, now estimated at ~7 per 100,000 per year in the United States, due in part to increased incidental detection on cross-sectional imaging. The prevalence of NETs exceeds that of pancreatic adenocarcinoma, esophageal cancer, and gastric cancer. The most common GEP-NETs by primary site are: small intestine (~30%), rectum (~20%), pancreas (~15%), appendix (~10%), and stomach (~10%). Small intestinal NETs are most frequently diagnosed in the 6th decade; they are typically well-differentiated (G1/G2) but may present with…

Functional Syndromes

Approximately 20–40% of NETs are functionally active, secreting bioactive hormones that produce recognizable clinical syndromes. Functional status does not necessarily correlate with tumor grade or bulk. Carcinoid Syndrome: The most common functional NET syndrome, caused predominantly by serotonin (5-HT) secretion from metastatic small intestinal or other midgut NETs that has bypassed hepatic first-pass inactivation. Classic features: episodic flushing (cutaneous, red or violaceous), secretory diarrhea, bronchospasm, and carcinoid heart disease (tricuspid regurgitation and pulmonic stenosis…

Diagnosis & Imaging

Diagnosis of NETs requires integration of clinical presentation, biochemical markers, histopathology, and functional imaging. Biochemical Markers: • Chromogranin A (CgA): The most useful general NET biomarker; elevated in 60–80% of NETs. False positives occur with proton pump inhibitor use, renal insufficiency, and atrophic gastritis. Rising CgA correlates with tumor progression. • 24-hour urinary 5-HIAA (5-hydroxyindoleacetic acid): Elevated in carcinoid syndrome; dietary interference (avoid bananas, walnuts, avocados for 48h before collection). Serum 5-HIAA assays are also available. •…

Surgery & Local Therapy

Surgery is the only potentially curative treatment for localized NETs and plays an important role even in metastatic disease. Localized Non-functional PNETs: Observation is appropriate for small ( 95%). Right hemicolectomy is indicated for tumors >2 cm, involvement of the appendiceal base/mesoappendix, or G2 grade. Liver-Directed Therapy for Metastatic NETs: Cytoreductive surgery (debulking) of hepatic metastases is pursued at specialized centers when ≥90% of tumor burden can be removed; 5-year OS ~60–80% at expert institutions. Liver transplantation for unresectable NET liver metastases is…

Medical Therapy: SSAs, PRRT & Targeted Agents

Medical management of NETs encompasses somatostatin analogs as the backbone for symptom control and tumor stabilization, with PRRT and targeted agents for progressive disease. Somatostatin Analogs (SSAs): • Octreotide LAR (long-acting release) and lanreotide Autogel: First-line for hormonal symptom control in functional NETs and for antiproliferative intent in well-differentiated, SSTR-positive G1/G2 NETs. PROMID trial (2009) [6]: Octreotide LAR significantly prolonged time-to-progression vs. placebo in metastatic midgut NETs. CLARINET trial (2014) [7]: Lanreotide significantly prolonged PFS…

PRRT Patient Selection & Eligibility

Peptide receptor radionuclide therapy (PRRT) with Lu-177 dotatate (Lutathera) requires careful patient selection across three domains: functional imaging confirmation of somatostatin receptor expression, tumor and patient fitness criteria, and absence of disqualifying exclusions. Practical referral note: PRRT must be administered at a certified nuclear medicine center (typically academic medical centers or specialized oncology programs). Refer patients early — before exhausting all other lines — to allow for institutional scheduling (typically 4–8 week lead time), insurance prior…

Cytotoxic Chemotherapy: Sequencing by NET Subtype

Cytotoxic chemotherapy occupies the later lines of NET therapy and is subtype-specific. The sequencing logic differs substantially between midgut/GI carcinoids and pancreatic NETs (pNETs), reflecting their distinct biology and chemosensitivity profiles. **GI Carcinoid / Midgut NET Treatment Ladder** Midgut NETs (small intestinal carcinoids) are relatively chemoresistant to alkylating agents. Cytotoxic chemotherapy is reserved for progressive disease after exhausting tumor-directed options: 1. SSA (octreotide LAR or lanreotide) — first-line antiproliferative; controls hormonal symptoms and…

MGMT Testing: How and When to Order

MGMT (O⁶-methylguanine-DNA methyltransferase) promoter methylation is the most important predictive biomarker before starting any temozolomide-containing regimen (CAPTEM or temozolomide monotherapy) in NETs. In MGMT-methylated pNETs, objective response rates exceed 40%; in unmethylated tumors the response rate falls to single digits. Testing is practical, widely available, and should be ordered at the same time as initial biopsy processing when cytotoxic therapy is anticipated. **When to order MGMT testing** Order MGMT methylation testing for any patient with a progressive…

pNET Systemic Therapy Comparison

Oncologists choosing between active systemic regimens for advanced, progressive pancreatic NETs (well-differentiated G1–G3) must weigh response rates, route of administration, eligibility requirements, and toxicity profiles side-by-side. The table below consolidates the pivotal trial evidence for all six major pNET options in one view. All regimens listed are for well-differentiated (NETs), not for poorly differentiated NEC — platinum-etoposide is reserved for NEC and is not included here. Sequencing is guided by SSTR receptor status (required for PRRT), MGMT methylation (predictive for…